Related Experiment Video

Updated: May 18, 2026

Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease
04:41

Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease

Published on: July 3, 2018

Value and level of galectin-3 in acute myocardial infarction patients undergoing primary percutaneous coronary

Tzu-Hsien Tsai1, Pei-Hsun Sung, Li-Teh Chang

  • 1Division of Cardiology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung, Taiwan.

Journal of Atherosclerosis and Thrombosis
|October 6, 2012
PubMed

Insights

Elevated galectin-3 levels in ST-segment elevation myocardial infarction (STEMI) patients predict poor 30-day outcomes. High galectin-3 is a strong predictor of major adverse clinical outcomes after primary percutaneous coronary intervention.

Area of Science:

  • Cardiology
  • Biomarkers
  • Clinical Research

Background:

  • ST-segment elevation myocardial infarction (STEMI) is a critical cardiovascular event.
  • Identifying reliable prognostic biomarkers is crucial for managing STEMI patients.
  • Galectin-3 is a protein with potential roles in cardiac remodeling and inflammation.

Purpose of the Study:

  • To investigate the association between circulating galectin-3 levels and 30-day prognostic outcomes.
  • To determine if galectin-3 can predict major adverse clinical outcomes (MACO) in STEMI patients undergoing primary percutaneous coronary intervention (PCI).

Main Methods:

  • Blood samples were collected from 196 STEMI patients treated with primary PCI and 30 healthy controls.
  • Circulating galectin-3 levels were measured using enzyme-linked immunosorbent assay (ELISA).
  • Statistical analyses, including multivariate analysis, were performed to assess the predictive value of galectin-3.

Main Results:

  • STEMI patients exhibited significantly higher galectin-3 levels compared to healthy controls (p<0.001).
  • Higher galectin-3 levels (≥7.67 ng/mL) were associated with older age, lower ejection fraction, and increased comorbidities.
  • Elevated galectin-3 was a strong independent predictor of 30-day MACO, including advanced congestive heart failure and mortality (p<0.0001).

Conclusions:

  • Circulating galectin-3 is significantly elevated in STEMI patients.
  • High galectin-3 levels are associated with adverse clinical characteristics and outcomes.
  • Galectin-3 shows promise as a valuable biomarker for predicting 30-day MACO in STEMI patients undergoing primary PCI.
Abstract

More Related Videos

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction05:26

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction

Published on: May 28, 2019

Related Concept Videos

Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...